重大事件
即時報告
8-K
2026-07-17
Karyopharm Therapeutics推高層留任計劃 總裁獲172.5萬美元現金獎勵
AI 繁中摘要
Karyopharm Therapeutics Inc. 於2026年7月13日提交8-K申報文件 📄，宣佈推出「2026年領導層現金留任計劃」。該計劃旨在公司預計迎來多項重要催化劑的關鍵時期，透過一次性現金獎勵留住核心高層的經驗與專業知識，並取代原有的2026年度花紅計劃。
計劃涵蓋四位高管，獎勵金額如下：
- 總裁兼CEO Richard Paulson：172.5萬美元
- 執行副總裁、開發總監 Stuart Poulton：64萬美元
- 執行副總裁、首席醫療官兼研究主管 Reshma Rangwala 醫生：72.5萬美元
- 執行副總裁、CFO兼財務總監 Lori Macomber：62.5萬美元
獎勵設有回報條款：若參與者在付款日起計12個月內（或發生合資格企業事件後30天，以較早者為準）因非公司無故解僱、非因參與者有正當理由辭職、或非因死亡/永久殘疾而離職，須全數或部分退還獎勵。此外，該計劃下支付的金額會抵銷原有遣散安排中應付的款項。
對投資者而言，此舉有助降低關鍵高層在催化劑前夕離職的風險 🛡️，但同時增加短期現金開支（總額約372萬美元）。計劃反映管理層對未來股價催化劑的信心，但投資者需留意資金運用及潛在遣散成本節省。
展開英文正文
8-K false 0001503802 0001503802 2026-07-13 2026-07-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2026 Karyopharm Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36167 26-3931704 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 85 Wells Avenue, 2nd Floor Newton, Massachusetts 02459 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (617) 658-0600 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 13, 2026, the Board of Directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”), upon recommendation of its Compensation Committee, implemented a retention program for certain employees of the Company, including each of the Company’s named executive officers and the Chief Financial Officer (the “2026 Leadership Cash Retention Program”). The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees. The 2026 Leadership Cash Retention Program replaces previously guaranteed amounts under the Company’s Annual Bonus Plan for 2026. Under the 2026 Leadership Cash Retention Program, the Company’s named executive officers and the Chief Financial Officer will receive lump sum cash retention awards in the following amounts: Richard Paulson, President and Chief Executive Officer, $1,725,000; Stuart Poulton, Executive Vice President, Chief Development Officer, $640,000; Dr. Reshma Rangwala, Executive Vice President, Chief Medical Officer and Head of Research, $725,000; and Lori Macomber, Executive Vice President, Chief Financial Officer and Treasurer, $625,000. Awards under the 2026 Leadership Cash Retention Program may be subject to repayment if the recipient’s employment is terminated for any reason other than by the Company without cause, by the participant for good reason or due to the participant’s death or permanent disability prior to the earlier of (i) 12 months from the payment date and (ii) 30 days following a qualifying corporate event. Amounts paid under the 2026 Leadership Cash Retention Program will reduce any amounts payable under previously agreed upon severance arrangements. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: July 17, 2026 By: /s/ Michael Mano Michael Mano Executive Vice President, Chief Legal Officer and Secretary 3